Greene John 4

What Happened
John Greene, a director of CRISPR Therapeutics (CRSP), was granted a derivative equity award on 2026-06-05 covering 13,000 shares. The grant is reported at $0.00 (no cash paid at grant); the filing identifies the award as options that will become exercisable as they vest.

Key Details

• Transaction date: 2026-06-05; reported filing date: 2026-06-09 (filed within the normal two-business-day Form 4 window).
• Consideration/price reported: $0.00 (grant of derivative security).
• Shares acquired: options to acquire 13,000 shares.
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Vesting footnote: options vest and become exercisable in 12 equal monthly installments, with the first installment vesting on June 30, 2026, and the final installment vesting on the earlier of the one-year anniversary of the grant or the 2027 Annual Meeting.
• No indication in this filing that shares were immediately sold or that a 10b5-1 plan or tax-withholding disposition was used.

Context
This is a compensation-style option grant to a director that vests over the coming year; such awards are common and do not represent an immediate purchase or sale of stock. Options become exercisable only as they vest, and any future exercises or sales would be reported separately.